Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients

Background: Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachmann, Friederike, Budde, Klemens, Suttorp, Norbert, Lingscheid, Tilman, Stegemann, Miriam Songa, Osmanodja, Bilgin, Schrezenmeier, Eva, Duettmann, Wiebke, Weber, Ulrike, Naik, Marcel, Lehner, Lukas Johannes, Kahl, Andreas, Duerr, Michael, Eckardt, Kai-Uwe, Waiser, Johannes, Choi, Mira, Halleck, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008834/
https://www.ncbi.nlm.nih.gov/pubmed/35431640
http://dx.doi.org/10.3389/ti.2022.10109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008834/
https://www.ncbi.nlm.nih.gov/pubmed/35431640
http://dx.doi.org/10.3389/ti.2022.10109

Ejemplares similares